The Effect of Calcium β-hydroxy-β-methylbutyrate (CaHMB) Supplementation in Sarcopenia in Liver Cirrhosis

Inclusion Criteria:

1. diagnosed of cirrhosis with imaging or liver biopsy;

2. diagnosis of portal hypertension with endoscopy or radiography；

3. assessed total muscle mass at the level of L3 (<42 cm2/m2 for male and <38 cm2/m2 forfemale)

4. has signed an informed consent form.

Exclusion Criteria:

1. diagnosed as hepatic cell cancer;

2. complicated with malignancy, renal failure, diabetes mellitus;

3. comorbidities including heart failure or pulmonary disease;

4. current use of drugs that affect skeletal muscle metabolism;

5. be allergic to the experimental food;

6. participated other clinical trials in the past 3 months;

7. other conditions that researchers consider not suitable for this study